title: When should therapy be reinstituted for relapsed Wegener's granulomatosis?
authors.affiliation: Department of Otolaryngology, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo Bunkyo-ku, Tokyo 113-8655, Japan. sakamoto@rigid.com
authors.forename: Masayuki
authors.initials: M
authors.lastname: Sakamoto
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Uno
authors.forename: Kenji
authors.initials: K
authors.lastname: Takagi
authors.forename: Ryuzaburo
authors.initials: R
authors.lastname: Higo
mesh_terms: D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D004844:Epistaxis / Q000188:drug therapy; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000627:therapeutic use; D014890:Granulomatosis with Polyangiitis / Q000188:drug therapy*; D006469:Hemoptysis / Q000188:drug therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D015508:Nasal Obstruction / Q000188:drug therapy; D009668:Nose Diseases / Q000188:drug therapy*; D011239:Prednisolone / Q000627:therapeutic use; D019233:Retreatment
chemical_list: D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D011239:Prednisolone